Core Viewpoint - Addex Therapeutics reported its full-year 2024 financial results, highlighting progress in clinical development and a significant net profit from discontinued operations, primarily due to the sale of part of its business to Neurosterix [1][4][8]. Financial Performance - Total income for 2024 was CHF 410,000, a decrease of CHF 1.2 million from CHF 1.6 million in 2023 [4][11]. - Research and Development (R&D) expenses decreased to CHF 854,000 from CHF 1.2 million, while General and Administrative (G&A) expenses also decreased to CHF 2.3 million from CHF 2.7 million [4][12]. - The total operating loss increased to CHF 2.8 million in 2024 from CHF 2.2 million in 2023 [4][13]. - Net loss from continuing operations was CHF 4.9 million, an increase of CHF 2.4 million compared to CHF 2.5 million in 2023 [4][13]. - The company reported a net profit of CHF 7.1 million for the period, primarily due to a net profit from discontinued operations of CHF 12.0 million [9]. Corporate Developments - The company launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A funding to advance its preclinical portfolio [6][7]. - Indivior selected a GABAB PAM drug candidate for development in substance use disorders, while Addex selected its own GABAB PAM for chronic cough [2][6]. - Addex regained full control of its mGlu2 PAM asset, ADX71149, and repositioned dipraglurant for brain injury recovery [2][6]. Cash Position - Cash and cash equivalents decreased to CHF 3.3 million at the end of 2024 from CHF 3.9 million at the end of 2023, primarily due to cash used in operating activities [10].

Core Viewpoint - Addex Therapeutics will announce its Full-Year 2024 Financial Results on April 25, 2025, and provide a business update along with a review of its product pipeline during a teleconference and webcast [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4]. - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [4]. - The company has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders and is advancing its own GABAB PAM program for chronic cough [4]. - Addex holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs targeting schizophrenia, mood disorders, and mild neurocognitive disorders [4]. - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [4].